Development and validation of an individualized immune prognostic model in stage I-III lung squamous cell carcinoma.

ABSTRACT: Lung squamous cell carcinoma (LUSC) possesses a poor prognosis even for stages I-III resected patients. Reliable prognostic biomarkers that can stratify and predict clinical outcomes for stage I-III resected LUSC patients are urgently needed. Based on gene expression of LUSC tissue samples from five public datasets, consisting of 687 cases, we developed an immune-related prognostic model (IPM) according to immune genes from ImmPort database. Then, we comprehensively analyzed the immune microenvironment and mutation burden that are significantly associated with this model. According to the IPM, patients were stratified into high- and low-risk groups with markedly distinct survival benefits. We found that patients with high immune risk possessed a higher proportion of immunosuppressive cells

SUBMITTER: Yang QF 

PROVIDER: S-EPMC8209222 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature